Research progress of hyperreflective foci in optical coherence tomography images in ocular diseases_Chinese Journal of Ocular Fundus Diseases

Authors：

Li Wenjing ,  Wan Guangming

Department of Ophthalmology, The First Affiliated Hospital of Zhengzhou University, Henan Engineering Research Center for Prevention and Treatment of Ocular Fundus Disease and Ocular Trauma, Zhengzhou 450052, China;

Corresponding author：

Wan Guangming, Email: wgm6608@163.com

Keywords：

Hyperreflective foci; Ocular disease; Optical coherence tomography; Review

DOI：

10.3760/cma.j.cn511434-20241104-00405

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Hyperreflective foci (HRF) were defined as well-circumscribed and scattered dots with hyperreflective signals in optical coherence tomography (OCT). HRF can be seen in the vitreous cavity as well as the retinal and choroidal layers. Different OCT examination equipment and modes have differences in HRF detection results, and HRF counting methods gradually develop from manual counting to semi-automatic counting and automatic counting. HRF may be lens fragments, inflammatory cells, migrating photoreceptor complexes, exuded proteins or lipids, activated microglia, degenerated photoreceptor cells, migrating retinal pigment epithelial cells, and degraded lipofuscin deposits. The number and distribution of HRF are associated with the progression and the prognosis of a variety of ocular diseases, such as diabetic retinopathy, age-related macular degeneration, central serous chorioretinopathy, retinal dystrophy, etc. HRF are clinically important in guiding the personalized treatment of patients.

Citation： Li Wenjing, Wan Guangming. Research progress of hyperreflective foci in optical coherence tomography images in ocular diseases. Chinese Journal of Ocular Fundus Diseases, 2025, 41(5): 398-403. doi: 10.3760/cma.j.cn511434-20241104-00405 Copy

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.	Wong BS, Sharanjeet-Kaur S, Ngah NF, et al. The correlation between hemoglobin a1c (Hba1c) and hyperreflective dots (HRD) in diabetic patients[J/OL]. Int J Environ Res Public Health, 2020, 17(9): 3154[2020-05-01]. https://pubmed.ncbi.nlm.nih.gov/32369922/. DOI: 10.3390/ijerph17093154.
19.
20.
21.
22.	Huang CH, Yang CH, Hsieh YT, et al. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy[J/OL]. Sci Rep, 2021, 11(1): 5103[2021-04-03]. https://pubmed.ncbi.nlm.nih.gov/33658601/. DOI: 10.1038/s41598-021-84553-7.
23.	Murakami T, Suzuma K, Uji A, et al. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema[J/OL]. Jpn J Ophthalmol, 2018, 62(3): 292-301[2018-05-19]. https://pubmed.ncbi.nlm.nih.gov/29460019/. DOI: 10.1007/s10384-018-0575-8.
24.	Park YG, Choi MY, Kwon JW. Factors associated with the duration of action of dexamethasone intravitreal implants in diabetic macular edema patients[J/OL]. Sci Rep, 2019, 9(1): 19588[2019-12-20]. https://pubmed.ncbi.nlm.nih.gov/31862943/. DOI: 10.1038/s41598-019-56143-1.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.	Mao J, Chen N, Zhang S, et al. Association between inflammatory cytokines in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy[J/OL]. Front Med (Lausanne), 2022, 9: 973025[2022-09-23]. https://pubmed.ncbi.nlm.nih.gov/36213652/. DOI: 10.3389/fmed.2022.973025.
35.
36.
37.	Gergely R, Kovács I, Récsán Z, et al. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy[J/OL]. Sci Rep, 2020, 10(1): 16621[2020-10-06]. https://pubmed.ncbi.nlm.nih.gov/33024222/. DOI: 10.1038/s41598-020-73959-4.
38.
39.
40.
41.	Parajuli A, Joshi P. Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy[J/OL]. BMJ Open Ophthalmol, 2020, 5(1): e000540[2020-12-01]. https://pubmed.ncbi.nlm.nih.gov/33305002/. DOI: 10.1136/bmjophth-2020-000540.
42.	Mirshahi R, Naseripour M, Ghomashi A, et al. Clinical predictive factors and imaging biomarkers of treatment response to half dose pdt in patients with chronic central serous chorioretinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2024, 48: 104224[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/38801855/. DOI: 10.1016/j.pdpdt.2024.104224.
43.
44.
45.
46.
47.	Li Z, Deng X, Lu T, et al. Hyperreflective material serves as a potential biomarker of dyslipidemia in diabetic macular edema[J/OL]. Photodiagnosis Photodyn Ther, 2022, 39: 102903[2022-05-06]. https://pubmed.ncbi.nlm.nih.gov/35533992/. DOI: 10.1016/j.pdpdt.2022.102903.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.	Horozoglu F, Sener H, Polat OA, et al. Predictive impact of optical coherence tomography biomarkers in anti-vascular endothelial growth factor resistant macular edema treated with dexamethasone implant[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103167[2022-10-17]. https://pubmed.ncbi.nlm.nih.gov/36261095/. DOI: 10.1016/j.pdpdt.2022.103167.
58.	Predović J, Bosnar D, Marković L, et al. Vitreous hyper-reflective dots and the macular thickness after cataract surgery[J/OL]. PLoS One, 2024, 19(4): e0300148[2024-04-09]. https://pubmed.ncbi.nlm.nih.gov/38593138/. DOI: 10.1371/journal.pone.0300148.
59.
60.

1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18. Wong BS, Sharanjeet-Kaur S, Ngah NF, et al. The correlation between hemoglobin a1c (Hba1c) and hyperreflective dots (HRD) in diabetic patients[J/OL]. Int J Environ Res Public Health, 2020, 17(9): 3154[2020-05-01]. https://pubmed.ncbi.nlm.nih.gov/32369922/. DOI: 10.3390/ijerph17093154.
19.
20.
21.
22. Huang CH, Yang CH, Hsieh YT, et al. Hyperreflective foci in predicting the treatment outcomes of diabetic macular oedema after anti-vascular endothelial growth factor therapy[J/OL]. Sci Rep, 2021, 11(1): 5103[2021-04-03]. https://pubmed.ncbi.nlm.nih.gov/33658601/. DOI: 10.1038/s41598-021-84553-7.
23. Murakami T, Suzuma K, Uji A, et al. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema[J/OL]. Jpn J Ophthalmol, 2018, 62(3): 292-301[2018-05-19]. https://pubmed.ncbi.nlm.nih.gov/29460019/. DOI: 10.1007/s10384-018-0575-8.
24. Park YG, Choi MY, Kwon JW. Factors associated with the duration of action of dexamethasone intravitreal implants in diabetic macular edema patients[J/OL]. Sci Rep, 2019, 9(1): 19588[2019-12-20]. https://pubmed.ncbi.nlm.nih.gov/31862943/. DOI: 10.1038/s41598-019-56143-1.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34. Mao J, Chen N, Zhang S, et al. Association between inflammatory cytokines in the aqueous humor and hyperreflective foci on optical coherence tomography in patients with neovascular age-related macular degeneration and polypoidal choroidal vasculopathy[J/OL]. Front Med (Lausanne), 2022, 9: 973025[2022-09-23]. https://pubmed.ncbi.nlm.nih.gov/36213652/. DOI: 10.3389/fmed.2022.973025.
35.
36.
37. Gergely R, Kovács I, Récsán Z, et al. Predictive factors of selective mineralocorticoid receptor antagonist treatment in chronic central serous chorioretinopathy[J/OL]. Sci Rep, 2020, 10(1): 16621[2020-10-06]. https://pubmed.ncbi.nlm.nih.gov/33024222/. DOI: 10.1038/s41598-020-73959-4.
38.
39.
40.
41. Parajuli A, Joshi P. Factors influencing the episode duration and the anatomical and functional outcome in cases of acute central serous chorioretinopathy[J/OL]. BMJ Open Ophthalmol, 2020, 5(1): e000540[2020-12-01]. https://pubmed.ncbi.nlm.nih.gov/33305002/. DOI: 10.1136/bmjophth-2020-000540.
42. Mirshahi R, Naseripour M, Ghomashi A, et al. Clinical predictive factors and imaging biomarkers of treatment response to half dose pdt in patients with chronic central serous chorioretinopathy[J/OL]. Photodiagnosis Photodyn Ther, 2024, 48: 104224[2024-05-25]. https://pubmed.ncbi.nlm.nih.gov/38801855/. DOI: 10.1016/j.pdpdt.2024.104224.
43.
44.
45.
46.
47. Li Z, Deng X, Lu T, et al. Hyperreflective material serves as a potential biomarker of dyslipidemia in diabetic macular edema[J/OL]. Photodiagnosis Photodyn Ther, 2022, 39: 102903[2022-05-06]. https://pubmed.ncbi.nlm.nih.gov/35533992/. DOI: 10.1016/j.pdpdt.2022.102903.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57. Horozoglu F, Sener H, Polat OA, et al. Predictive impact of optical coherence tomography biomarkers in anti-vascular endothelial growth factor resistant macular edema treated with dexamethasone implant[J/OL]. Photodiagnosis Photodyn Ther, 2023, 42: 103167[2022-10-17]. https://pubmed.ncbi.nlm.nih.gov/36261095/. DOI: 10.1016/j.pdpdt.2022.103167.
58. Predović J, Bosnar D, Marković L, et al. Vitreous hyper-reflective dots and the macular thickness after cataract surgery[J/OL]. PLoS One, 2024, 19(4): e0300148[2024-04-09]. https://pubmed.ncbi.nlm.nih.gov/38593138/. DOI: 10.1371/journal.pone.0300148.
59.
60.

Previous Article
特发性视网膜血管炎、动脉瘤、视神经视网膜综合征
Next Article
Research progress on lattice degeneration of retina

Chinese Journal of Ocular Fundus Diseases

Research progress of hyperreflective foci in optical coherence tomography images in ocular diseases

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content